16 adult patients with acute myelogenous leukemia received TAD induction
chromotherapy consisting of 7-day courses of 6-thioguanine (100mg/㎡, every 12 hours)
and ars-C (100mg/㎡, daily), and 3-day courses of daunorublcin (45mg/㎡, daily). The
patients who didn't achieve complete remission after the first course of TAD received
an additional course of a modified TAD consisting of 5-day courses of 6-thioguanine
and ara-C, and 2-day courses of daunorubicin. Drug doses were identical to those used
in the first course of TAD. Patients who achieved complete remission after the first or
the second course of TAD received an alternating maintenance chemotherapy with
ara-C/6-thioguanine and ara-C/daunorubicin(maximum eight courses). 12 patients(75%)
achieved complete remission. Median remission duration was 13 months and median
survival 13 months. Bone marrown was profoundly depreseed in most patients after
TAD. Other toxicities of TAD were anorexia, nausea, vomiting, headache, alopecia,
stomatitis, diarrhea, hepatotoxicity and skin discoloration. No substantial cardiac, renal or
neurological toxicity was observed. These results indicate that TAD regimen is effective
in the treatment of acute myelogenous leukemia.

Keywords: Chemotherapy, Acute Myelogenous Leukemia